Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus surgery in recurrent nasopharyngeal carcinoma
NCT04778956Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Mar 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04778956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778956.